DNTH · Dianthus Therapeutics, Inc. /DE/ · Webcasts, Transcripts & Audio
$88.90
+0.85 (+0.97%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the "issuance date") As of the issuance date, the Company expects that its existing cash, cash equivalents and investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date.”View the 10-Q filed Aug 4, 2026
Market Cap
$5.23B
Shares
55.93M
Volume · Oct 1
767.07K
Avg daily vol (3M)
833.35K
Dianthus Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Dianthus Therapeutics, Inc. (DNTH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Conference
Investor event
2026-09-10
Dianthus Therapeutics, Inc. (DNTH) September 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-09
Dianthus Therapeutics, Inc. (DNTH) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-09
Dianthus Therapeutics, Inc. (DNTH) Q4 2025 Earnings Call Transcript
Confident tone
Clasipabart efficacy and differentiation vs. relipobart
Broader neuromuscular pipeline
Part B trial design optimization
Revenue
$284,000*
▼ 78.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q2
2022-08-04
Dianthus Therapeutics, Inc. (DNTH) Q2 2022 Earnings Call
Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Dianthus Therapeutics, Inc. (DNTH) Q4 2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q4
2021-01-11
Dianthus Therapeutics, Inc. (DNTH) Q4 2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q1
2020-05-07
Dianthus Therapeutics, Inc. (DNTH) Q1 2020 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Dianthus Therapeutics, Inc. (DNTH) Q4 2019 Earnings Call
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–8 of 8 webcasts